Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2019-08-06 Interim / Quarterly Rep…
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2019
2019-08-06 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the issuance of senior secured notes and warrants, the entry into an indenture, termination of a prior credit agreement, and related financing activities. It includes detailed terms of the notes, warrants, and agreements, indicating it is an announcement of financing activities rather than a full financial report or earnings release. The document is about capital raising and financing arrangements, which fits the Capital/Financing Update category. It is not an annual or quarterly report, audit report, or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2019-07-16 English
PRIMARY DOCUMENT
Director's Dealing
2019-07-02 English
PRIMARY DOCUMENT
Director's Dealing
2019-07-02 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 13, 2019, for Aquestive Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the 2019 Annual Meeting of Stockholders, including election of directors, ratification of the independent auditor, and approval of an employee stock purchase plan. The document provides detailed voting results for these matters. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4082 characters, which is short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement or Regulatory Filing. The presence of voting results and the nature of the content clearly classify it as DVA.
2019-06-18 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.